Plain-English translation of NCT04580420 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a medication called to see if it can safely help people with primary hyperoxaluria type 1 (a rare inherited condition where the body produces too much of a substance called oxalate that damages the kidneys) who have severe kidney disease. Researchers want to understand whether this medication can reduce oxalate levels and help protect kidney function in patients of all ages, from infants to adults.
Primary hyperoxaluria type 1 is a serious genetic disease with very few treatment options, especially for patients whose kidneys are already severely damaged. This trial is testing whether this new medication can lower the harmful oxalate buildup and potentially slow or prevent further kidney damage in these patients.
You likely qualify if…
You likely don't qualify if…
If you join, you would receive a monthly injection of the medication at clinic visits for the first 6 months. After that, if the treatment is working well, you can continue in an extended phase where you visit the clinic every 3 months for up to 5 years, with the option to self-administer the injection at home or have a nurse help you. Throughout the study, your doctors will monitor your kidney function and oxalate levels with blood tests to see how the medication is working.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States
France